Prolastin®-C

Understanding Prolastin®-C

Prolastin®-C is an alpha-1 proteinase inhibitor (A1PI) therapy used to treat individuals with Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder that can lead to emphysema and progressive lung disease. Prolastin®-C works by replacing the missing alpha-1 antitrypsin (AAT) in the body, helping to protect the lungs from damage caused by enzymes such as neutrophil elastase. This therapy is designed to preserve lung function and slow disease progression, offering significant benefits for patients with AATD. Prolastin®-C is an enhanced formulation of the original Prolastin® therapy.

How Prolastin®-C Works:

• Replaces missing alpha-1 antitrypsin (AAT) to protect lung tissue.
• Slows lung function decline in patients with Alpha-1 Antitrypsin Deficiency (AATD).
• Reduces inflammation and prevents further lung tissue damage.

FDA Approval:

• Prolastin®-C: Originally approved in 1988 (as Prolastin®); Prolastin®-C was later introduced as an enhanced formulation.

For more information, please visit the Prolastin®-C patient website and speak with your healthcare provider to determine if Prolastin®-C is the right treatment option for you.